Clinical considerations of anticoagulation therapy for patients with atrial fibrillation  

作　　者：Shu ZHANG 

机构地区：[1]Arrhythmias Center and Clinical EP Lab.,Cardiovascular Institute and Fuwai Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2012年第8期609-615,共7页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：Project (No. 200902001) supported by the Research on Monitoring,Prevention, Early-Warning, Diagnosis,and Therapy of Cardiovascular Diseases Part Ⅱ:Community Based Approach for Atrial Fibrillation and Sudden Cardiac Death, China

摘　　要：Atrial fibrillation (AF) increases the risk of stroke. New anticoagulation agents have recently provided alternative and promising approaches. This paper reviews the current state of anticoagulation therapy in AF patients, focusing on various clinical scenarios and on comparisons, where possible, between western and eastern populations.Atrial fibrillation （AF） increases the risk of stroke. New anticoagulation agents have recently provided alternative and promising approaches. This paper reviews the current state of anticoagulation therapy in AF patients, focusing on various clinical scenarios and on comparisons, where possible, between western and eastern populations.

关 键 词：Anticoagulation therapy Atrial fibrillation Warfarin DABIGATRAN Riveroxaban APIXABAN 

分 类 号：R541.7[医药卫生—心血管疾病]